NASDAQ:ETON - Eton Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 83.02 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.83
▲ +0.31 (4.75%)
1 month | 3 months | 12 months
Get New Eton Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETON

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.50
▲ +83.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eton Pharmaceuticals in the last 3 months. The average price target is $12.50, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 83.02% upside from the last price of $6.83.

Buy

The current consensus among 2 investment analysts is to buy stock in Eton Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2021B. RileyLower Price TargetBuy$13.00 ➝ $11.00Medium
i
3/17/2021HC WainwrightLower Price TargetBuy$15.00 ➝ $14.00Medium
i
1/4/2021HC WainwrightLower Price TargetBuy$20.00 ➝ $15.00N/A
i
9/30/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $20.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/24/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/26/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $18.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/15/2020B. RileyLower Price TargetBuy$12.00 ➝ $10.00Medium
i
3/30/2020HC WainwrightBoost Price TargetBuy$23.00 ➝ $26.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/19/2020HC WainwrightReiterated RatingBuy$23.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/28/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $23.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/30/2019HC WainwrightReiterated RatingBuy$21.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
10/23/2019HC WainwrightReiterated RatingBuy$18.00 ➝ $21.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/20/2019B. RileyInitiated CoverageBuy$13.50High
i
Rating by A. D'silva at B. Riley
8/5/2019Lake Street CapitalInitiated CoverageBuyLow
i
8/5/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by R. Selvaraju at HC Wainwright
6/21/2019HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Low
i
Rating by R. Selvaraju at HC Wainwright
6/10/2019HC WainwrightInitiated CoverageBuy$15.00High
i
Rating by R. Selvaraju at HC Wainwright
(Data available from 6/16/2016 forward)
Eton Pharmaceuticals logo
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Read More

Today's Range

Now: $6.83
$6.27
$8.35

50 Day Range

MA: $7.69
$5.95
$8.85

52 Week Range

Now: $6.83
$4.80
$10.30

Volume

7,665,158 shs

Average Volume

364,787 shs

Market Capitalization

$167.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Eton Pharmaceuticals?

The following sell-side analysts have issued reports on Eton Pharmaceuticals in the last twelve months: B. Riley, HC Wainwright, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ETON.

What is the current price target for Eton Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Eton Pharmaceuticals in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 77.3%. HC Wainwright has the highest price target set, predicting ETON will reach $14.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $11.00 for Eton Pharmaceuticals in the next year.
View the latest price targets for ETON.

What is the current consensus analyst rating for Eton Pharmaceuticals?

Eton Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETON will outperform the market and that investors should add to their positions of Eton Pharmaceuticals.
View the latest ratings for ETON.

What other companies compete with Eton Pharmaceuticals?

How do I contact Eton Pharmaceuticals' investor relations team?

Eton Pharmaceuticals' physical mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company's listed phone number is 847-787-7361 and its investor relations email address is [email protected] The official website for Eton Pharmaceuticals is www.etonpharma.com.